Clinical Trial Update: To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Viaject 7 to insulin lispro in type 1 diabetes patients using insulin pumps, evaluating post-prandial glycemia safety and tolerability; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Viaject 7
• insulin lispro (insulin lispro)

Snippet

Sponsor: Biodel | Conditions: Type 1 Diabetes Mellitus | Phase 3 | Status: COMPLETED